Marker Therapeutics, Inc. (MRKR)

Marker Therapeutics' stock price has experienced fluctuations over the past six months, declining by 50.56% between January 6, 2025, and January 2, 2026. Following its earnings release on November 14, 2025, where the company reported earnings per share of ($0.12), beating the consensus estimate of ($0.69), MRKR shares gained +3.5% the day after the announcement. Since that earnings release 58 days prior to January 14, 2026, the stock has drifted +116.7% higher, trading in a range between $0.93 and $2.46. Positive clinical trial updates and presentations have also impacted the stock, including presentations on MT-601 and reports on Multi-Antigen Targeted T cells.

Demand for Marker Therapeutics' products is primarily driven by clinical trial outcomes, regulatory approvals, and disease prevalence, rather than traditional seasonal patterns. Therefore, conventional demand seasonality is not applicable to Marker Therapeutics.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for various cancers. Their core technology involves multi-tumor associated antigen (MultiTAA)-specific T cells that recognize and eliminate tumor cells. Key product candidates include MT-401-OTS for AML and MDS, MT-601 for lymphoma and pancreatic cancer, and Multi-Antigen Targeted T cells, which have shown promising results in clinical trials.

Marker Therapeutics is headquartered in Houston, Texas, United States. Clinical trials have been conducted across multiple U.S. clinical sites. The company's stock is listed on NASDAQ (Small cap) in the United States.

Marker Therapeutics has a generally positive brand reputation, with a consensus "Buy" rating from Wall Street analysts and a significantly higher average price target. Positive news releases regarding clinical trial progress and the initiation of the Off-the-Shelf program contribute positively to the company's reputation. There were no specific events identified that negatively impacted Marker Therapeutics' reputation in the past year.

Approximately 20.69% to 22.39% of Marker Therapeutics' shares are held by institutions, including NEA Management Company, LLC, Blue Owl Capital Holdings LP, and Vanguard Group Inc. Individual insider shareholders hold 7.80% of the company's stock.